Export-Import Bank of Korea to Provide 350 Billion Won Support for Celltrion's U.S. Production Facility Acquisition
Operation of the Advanced Strategic Industry Preferential Support Program
The Export-Import Bank of Korea announced on November 25 that it will provide 350 billion won in financing for Celltrion's acquisition (M&A) of Eli Lilly's production facility in the United States. The bank explained that, with this financial support, Celltrion will be able to establish an integrated production and sales system in the United States, the world's largest pharmaceutical market.
The United States is the second-largest market after Europe in the field of biosimilars (biopharmaceutical generics), where domestic bio companies have been excelling.
The Export-Import Bank of Korea stated that it is actively supporting the global competitiveness of K-Bio by providing programs such as the "Advanced Strategic Industry Preferential Support Program" to assist Korean bio companies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from the Export-Import Bank of Korea said, "Through this acquisition of a production facility, Celltrion will be able to establish a stable supply chain, avoiding risks such as trade conflicts and logistics crises, and expand its local sales base. As a leading player in K-Bio, Celltrion is also expected to contribute to the development of the related industrial ecosystem by fostering co-growth between 'anchor-biotech' (leading conglomerates and innovative bio ventures)."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.